Publication: Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done.
No Thumbnail Available
Identifiers
Date
2019
Authors
Llerena, Susana
Cabezas, Joaquín
Cuadrado, Antonio
Manuel Olmos, José
González, Marta
García, Federico
Cobo, Carmen
Crespo, Javier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.
Description
MeSH Terms
Amides
Antiviral Agents
Benzofurans
Carbamates
Cyclopropanes
Drug Resistance, Viral
Drug Therapy, Combination
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Imidazoles
Male
Middle Aged
Quinoxalines
RNA, Viral
Retreatment
Sofosbuvir
Sulfonamides
Treatment Failure
Antiviral Agents
Benzofurans
Carbamates
Cyclopropanes
Drug Resistance, Viral
Drug Therapy, Combination
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Imidazoles
Male
Middle Aged
Quinoxalines
RNA, Viral
Retreatment
Sofosbuvir
Sulfonamides
Treatment Failure
DeCS Terms
CIE Terms
Keywords
Genotype 3, Grazoprevir + Elbasvir, Hepatitis C virus, Sofosbuvir, Treatment failure